237 related articles for article (PubMed ID: 29617673)
1. Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells.
Naguib A; Mathew G; Reczek CR; Watrud K; Ambrico A; Herzka T; Salas IC; Lee MF; El-Amine N; Zheng W; Di Francesco ME; Marszalek JR; Pappin DJ; Chandel NS; Trotman LC
Cell Rep; 2018 Apr; 23(1):58-67. PubMed ID: 29617673
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
3. Deguelin and Its Role in Chronic Diseases.
Boyd J; Han A
Adv Exp Med Biol; 2016; 929():363-375. PubMed ID: 27771933
[TBL] [Abstract][Full Text] [Related]
4. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2011 Dec; 129(12):2916-27. PubMed ID: 21472727
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylated Rotenoids Selectively Inhibit the Proliferation of Prostate Cancer Cells.
Russell DA; Bridges HR; Serreli R; Kidd SL; Mateu N; Osberger TJ; Sore HF; Hirst J; Spring DR
J Nat Prod; 2020 Jun; 83(6):1829-1845. PubMed ID: 32459967
[TBL] [Abstract][Full Text] [Related]
7. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.
Wang L; Xiong H; Wu F; Zhang Y; Wang J; Zhao L; Guo X; Chang LJ; Zhang Y; You MJ; Koochekpour S; Saleem M; Huang H; Lu J; Deng Y
Cell Rep; 2014 Sep; 8(5):1461-74. PubMed ID: 25176644
[TBL] [Abstract][Full Text] [Related]
8. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
9. Deguelin Attenuates Non-Small-Cell Lung Cancer Cell Metastasis by Upregulating PTEN/KLF4/EMT Signaling Pathway.
Lu G; Yao Y; Zhang X; Cui D; Zhou J
Dis Markers; 2022; 2022():4090346. PubMed ID: 35637651
[TBL] [Abstract][Full Text] [Related]
10. Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN
Pan H; Lu LY; Wang XQ; Li BX; Kelly K; Lin HS
Chin J Integr Med; 2018 Feb; 24(2):109-116. PubMed ID: 28578487
[TBL] [Abstract][Full Text] [Related]
11. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of Akt inhibitor deguelin on the growth of PC-3 prostate cancer cells].
Chen HB; Hu XH; Jiang KH; Zhu SL; Zhao CX; Yuan W; Lan Y; Chen S; Yuan HG; Song XF; Wang YL
Zhonghua Nan Ke Xue; 2013 Jun; 19(6):501-5. PubMed ID: 23862226
[TBL] [Abstract][Full Text] [Related]
13. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
14. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes
van de Ven AL; Tangutoori S; Baldwin P; Qiao J; Gharagouzloo C; Seitzer N; Clohessy JG; Makrigiorgos GM; Cormack R; Pandolfi PP; Sridhar S
Mol Cancer Ther; 2017 Jul; 16(7):1279-1289. PubMed ID: 28500233
[TBL] [Abstract][Full Text] [Related]
15. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
16. Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.
Ji BC; Yu CC; Yang ST; Hsia TC; Yang JS; Lai KC; Ko YC; Lin JJ; Lai TY; Chung JG
Oncol Rep; 2012 Apr; 27(4):959-64. PubMed ID: 22227970
[TBL] [Abstract][Full Text] [Related]
17. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
18. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
19. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
20. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
